Month: March 2025

Fourth quarter results compared to prior year:Orders grew 9%, driven by 12% broad-based growth in the Americas Gross margin improved 70 basis pointsFiscal 2025 results:Orders grew 4%, driven by 6% growth in the Americas compared to prior year Gross margin improved 110 basis points compared to prior year, including benefits from cost reduction initiatives Operating income margin reached 5.0%, an improvement of 130 basis points compared to the prior year Adjusted earnings per share exceeded company targets Returned $84 million to shareholders Total liquidity strengthened by $73 millionCompany provides financial targets for fiscal 2026 of mid-single digit organic revenue growth and modest adjusted operating margin expansionGRAND RAPIDS, Mich., March 26, 2025 (GLOBE NEWSWIRE) — Steelcase Inc. (NYSE: SCS) today reported...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower cost Growth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1 Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applications Continued advancements in animal and human health Cash and investment-grade securities of $9.3 million as of December 31, 2024 Financial results and business update conference call scheduled for 5:00 pm ET todayJUPITER, Fla., March 26, 2025 (GLOBE NEWSWIRE) —...

Full Year Revenues up in each of ACH & Complementary Services, Card and Output Solutions Business Units Record Full Year 2024 Dollar Processing Volume of $7.1 Billion, a 33% Increase Compared to Fiscal 2023; Transactions Processed also up a Strong 26% Year-over-Year Cash Position Increases to Record High of $8.1 Million SAN ANTONIO, March 26, 2025 (GLOBE NEWSWIRE) — Usio, Inc: (Nasdaq: USIO), a leading FinTech company that operates a full stack of integrated, cloud-based electronic payment and embedded financial solutions, today announced financial results for the fourth quarter and year ended December 31, 2024. Louis Hoch, Chairman and Chief Executive Officer of Usio, said, “We are delivering on our commitments as profitability improved, cash flow was strong, and revenue grew in each of our ACH & Complementary Services,...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate...

CULVER CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (NASDAQ: SNAL) (“Snail” or “the Company”), a leading, global independent developer and publisher of interactive digital entertainment, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter & Full Year 2024 HighlightsARK: Survival Ascended. On October 25, 2023, the Company launched its flagship remake of the ARK franchise leveraging Unreal Engine 5’s stunning graphics and introduced a game-altering cross-platform modding system, ushering in a new era of creativity.ARK: Survival Ascended was ranked the top #1 selling game on Steam on launch day.   Since its launch, ARK: Survival Ascended sold 3.4 million units and has an average of 94,000 daily active users (“DAUs”) with a peak of 308,000 DAUs.ARK:...